WuXi AppTec Opens Laboratory Testing Facility in NJ
WuXi AppTec has opened its expanded Laboratory Testing Division (LTD) facility in New Jersey. The grand opening event was attended by state and local officials including State Senator Linda Greenstein. The new facility will enhance WuXi's integrated testing service portfolio enabling drug developers to accelerate their projects from labs to patients.
The expansion will double total operation space to more than 115,000 square feet, and will create over 200 jobs. After the expansion, LTD's combined New Jersey operation will be one of the largest laboratories for preclinical and clinical drug development testing in the U.S.
The new site will establish a center of excellence for drug development and provide high quality services to the U.S. pharmaceutical and biotech industries.
"The Garden State continues to be an important life science hub. This expansion will allow our team to deliver high quality service with faster turnaround times, better leverage the resources and expertise of the local pharmaceutical and biotechnology community, and develop a stronger connection with our customers," said Jason Liu, senior vice president of WuXi AppTec and chief operating officer of the LTD.
"We are delighted for this opportunity to better serve our global customers and to support local economic development in New Jersey," said Ge Li, chairman and chief executive officer, WuXi AppTec. "We will continue to enhance WuXi's capabilities and capacities to enable our global partners to discover and develop drugs more efficiently and cost effectively ultimately benefitting patients worldwide."
WuXi AppTec is a global company headquartered in Shanghai, China. In addition to the New Jersey site, WuXi also has U.S. facilities in Philadelphia, PA; St. Paul, MN; Atlanta, GA; San Diego, CA; and Boston, MA.
Looking for chemical products? Let suppliers reach out to you!
JLL and Water Street Acquire Triplefin
AMRI Renews NIH Contract
2026-07-02
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
WuXi upgrades CAR-T offerings with new manufacturing platform
-
Eli Lilly to Raise UK Mounjaro Price 170 Percent Monthly Cost Jumps from £122 to £330
-
FDA Approves Precigen’s Papzimeos Immunotherapy 51 Percent of RRP Patients Avoid Surgery for One Year
-
Eli Lilly Strikes $1.3 Billion AI Deal with Superluminal for Next-Gen Obesity Drugs Targets GPCR Breakthrough
-
Novo Nordisk Launches Wegovy in South Africa One in Two Adults Faces Obesity as GLP-1 Drug Competition Heats Up
-
Trump Pressures 17 Pharma CEOs to Match US Drug Prices with Global Lows September 29 Deadline Set
-
Bayer Sets Aside $1.37 Billion for Roundup Lawsuits Raises 2025 Sales Forecast to €48 Billion
-
Mounjaro Reduces Heart Events by 8 Percent More Than Trulicity in 13,000-Patient Diabetes Trial
-
JB Pharma Q1 Net Profit Surges 14 Percent to ₹202 Crore Revenue Hits ₹1094 Crore with 30 Percent EBITDA Margin
-
Sun Pharma Halts US Expansion Amid 25 Percent Tariff Threat Net Profit Drops 20 Percent
Recommend Reading
-
Moderna to Cut 10 Percent of Staff as COVID Vaccine Sales Plunge Stock Drops 4 Percent
-
Pharma Tariff Risk Pushes Global Drugmakers to Rebuild U.S. Supply Chains
-
U.S. API Dependence Turns Pharmaceutical Ingredients Into a National Security Issue
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
Pharma’s Tightrope in 2026: Safety, Competition and the Future of Obesity Treatment Innovation
-
Rate of Change Turns Negative—Retail Prices for Refined Oil Products to Be Lowered This Round
-
Supply and Demand Expectations Gradually Weakening, PTA Prices Tend to Remain Weak
-
Cost Weakening Combined with Weak Demand: Toluene Market Shakes and Declines in February
-
Post-holiday Isobutanol Prices Rebound
-
Weakening Fundamentals Lead to Declining Prices for Polyester Staple Fiber